In this article, we will explore the future share price targets of Earum Pharma for the years 2025, 2026, 2028, 2030, 2040, and 2050. Additionally, we will discuss Earum Pharma’s fundamentals, market sentiment, financial performance, and quarterly reports to assist investors in making informed decisions.
About Earum Pharma
Earum Pharma is an emerging leader in the pharmaceutical sector, dedicated to pioneering advanced therapeutic solutions that address critical healthcare challenges. The company prioritizes the development of accessible, cost-effective medications targeting chronic illnesses, rare diseases, and generic drug markets. By integrating cutting-edge research with ethical practices, Earum Pharma aims to bridge gaps in global healthcare accessibility while maintaining rigorous compliance with international quality standards.
Driven by a patient-centric philosophy, the organization collaborates with medical experts, researchers, and sustainability advocates to ensure therapies are both safe and environmentally responsible. Its mission—rooted in scientific innovation and social responsibility—focuses on democratizing healthcare through scalable solutions that enhance quality of life across diverse populations.
Earum Pharma Fundamentals
| Description | Value |
|---|---|
| Company Name | Murae Organisor Ltd. |
| Sector | Pharmaceuticals |
| Established | 1912 |
| Website | earumpharma.com |
| Listing At | BSE |
| BSE Code | 542724 |
| Mkt Cap | ₹191Cr |
| Reserves and Surplus | ₹6.42Cr |
| ROE | 0.28% |
| ROCE | 0.79% |
| 52 Week High | ₹3.03 |
| 52 Week Low | ₹1.04 |
| P/E Ratio (TTM) | 41.20 |
| Industry P/E | 40.98 |
| P/B Ratio | 0.61 |
| Face Value | 2 |
| Book Value Per Share | ₹3.35 |
| EPS (TTM) | ₹0.05 |
| Dividend Yield | 0.00% |
| Debt to Equity | 0.98 |
| Total Revenue | ₹4.06Cr |
| Revenue Growth | -75.18% |
| Net Profit (Anual) | ₹0.05Cr |
| Profit Growth | -97.47% |
Returns in Past Year
| Year | Returns (%) |
|---|---|
| 2024 | 85.71% |
| 2023 | -53.72% |
| 2022 | -71.02% |
| 2021 | 15.49% |
| 2020 | 97.54% |
Earum Pharma Share Price Target 2025
Current market sentiment around Earum Pharma is highly bullish. The expected share price target for 2025 is estimated to be between ₹1.30 to ₹2.98.
| Year | Price Target (Min) | Price Target (Max) |
|---|---|---|
| 2025 | ₹1.30 | ₹2.98 |
Earum Pharma Share Price Target 2026
According to market analysts, Earum Pharma’s share price in 2026 is projected to range between ₹1.85 to ₹3.45.
| Year | Price Target (Min) | Price Target (Max) |
|---|---|---|
| 2026 | ₹1.85 | ₹3.45 |
Earum Pharma Share Price Target 2028
By 2028, the share price target for Earum Pharma is anticipated to be between ₹2.65 to ₹5.3, considering the company’s steady growth and expansion in defense contracts.
| Year | Price Target (Min) | Price Target (Max) |
|---|---|---|
| 2028 | ₹2.65 | ₹5.3 |
Earum Pharma Share Price Target 2030
Based on the company’s historical performance and ongoing projects, Earum Pharma’s share price in 2030 is expected to be between ₹3.86 to ₹6.79.
| Year | Price Target (Min) | Price Target (Max) |
|---|---|---|
| 2030 | ₹3.86 | ₹6.79 |
Earum Pharma Share Price Target 2040
Following the long-term trend, Earum Pharma’s share price in 2040 is likely to fall between ₹10.6 to ₹17.80.
| Year | Price Target (Min) | Price Target (Max) |
|---|---|---|
| 2040 | ₹10.6 | ₹17.80 |
Earum Pharma Share Price Target 2050
Considering the consistent growth trajectory and the company’s prominent role in defense manufacturing, Earum Pharma’s share price target for 2050 is expected to range from ₹15.4 to ₹30.7.
| Year | Price Target (Min) | Price Target (Max) |
|---|---|---|
| 2050 | ₹15.4 | ₹30.7 |
Strengths
- Valuation Metrics: With a trailing P/E ratio of 41.20, marginally above the industry average of 40.98, the stock appears moderately overvalued. However, a price-to-book (P/B) ratio of 0.61 signals potential undervaluation relative to its book value per share of ₹3.35, which exceeds its current market price.
- Legacy and Stability: Founded in 1912, Earum Pharma boasts a century-long legacy, underscoring its resilience and adaptability in a competitive industry.
- Operational Cash Flow: The company demonstrated improved financial health in 2022, generating ₹2.61 crore in operating cash flow—a positive indicator of liquidity.
Risks
- Financial Performance: Persistent declines in revenue and profitability raise concerns about growth sustainability. Recent quarters revealed alarming metrics, including a -104.35% profit margin in March 2024.
- Debt Concerns: A debt-to-equity ratio of 0.98 reflects heavy reliance on borrowed capital, amplifying risks if earnings fail to stabilize.
- Resource Efficiency: Subpar returns on equity and capital employed suggest inefficiencies in asset utilization.
- Investor Appeal: Absence of dividend payouts diminishes attractiveness to income-focused investors, while modest reserves (₹6.42 crore) limit financial flexibility.
Earum Pharma Quarterly Income Report
| Description | Sep 24 | Jun 24 | Mar 24 | Dec23 |
| Revenue + | ₹281.05Cr. | ₹58.01Cr. | ₹0.23Cr. | ₹0.40Cr. |
| Expenses + | ₹275.79Cr | ₹56.89Cr. | ₹0.47Cr. | ₹0.37Cr. |
| EBITDA | ₹5.26Cr | ₹1.12Cr. | ₹-0.24Cr. | ₹0.06Cr. |
| EBIT | ₹5.26Cr | ₹1.12Cr. | ₹-0.24Cr. | ₹0.04Cr. |
| Net Profit | ₹4.01Cr | ₹0.90Cr. | ₹-0.24Cr. | ₹0.04Cr. |
| Operating Profit Margin | 1.87% | 1.95% | -104.35% | 15% |
| Net Profit Margin | 1.43% | 1.55% | -104.35% | 10% |
| Earning Per Share | ₹0.06 | ₹0.01 | ₹-0.01 | ₹0.05 |
| Dividends Per Share | 0.00 | 0.00 | 0.00 | 0.70 |
Earum Pharma Annual Income Report
| Description | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|
| Total Revenue | ₹4.06Cr | ₹16.36Cr | ₹28.74Cr | ₹50.02Cr |
| Total Expenses | ₹3.99Cr | ₹13.56Cr | ₹25.66Cr | ₹49.90Cr |
| Profit/Loss | ₹0.05Cr | ₹1.98Cr | ₹2.22Cr | ₹0.09Cr |
| Net Profit Margin | 1.97% | 14.05% | 10.55% | 0.22% |
| Earning Per Share | ₹0.00 | ₹0.32 | ₹0.36 | ₹0.01 |
| EBITDA | ₹0.39 | ₹3.19 | ₹3.28 | ₹1.17 |
| EBIT | ₹0.34 | ₹3.09 | ₹3.16 | ₹1.05 |
| Operating Profit Margin | 15.35% | 22.64% | 15.59% | 2.85% |
| Dividends Per share | 0.00 | 0.00 | 0.00 | 0.00 |
Earum Pharma Cash Flow
| Particulars | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Opening Cash Balance | ₹-1.24Cr. | ₹0.03Cr. | ₹0.16Cr. | ₹0.02Cr. |
| Cash Flow From Operating Activities | ₹2.61Cr | ₹-7.10Cr. | ₹-3.45Cr. | ₹-0.48Cr. |
| Cash Flow From Investing Activities | ₹0.06Cr | ₹2.94Cr. | ₹-3.45Cr. | ₹-0.32Cr. |
| Cash Flow From Financing Activities | ₹-2.59Cr | ₹-2.90Cr. | ₹-6.76Cr. | ₹-0.94Cr. |
| Closing Cash Balance | ₹-1.15Cr | ₹-1.24Cr. | ₹0.03Cr. | ₹0.16Cr. |
| Net Change In Cash | ₹0.08 | ₹-1.26 | ₹-0.14 | ₹0.14 |
Earum Pharma Share Price History Chart
Earum Pharma Share Price Target 2025, 2026, 2028, 2030, 2040 to 2050
| Year | Price Target (Min) | Price Target (Max) |
|---|---|---|
| 2025 | ₹1.30 | ₹2.98 |
| 2026 | ₹1.85 | ₹3.45 |
| 2028 | ₹2.65 | ₹5.3 |
| 2030 | ₹3.86 | ₹6.79 |
| 2040 | ₹10.6 | ₹17.80 |
| 2050 | ₹15.4 | ₹30.7 |
Earum Pharma Shareholding Pattern
| Shareholder | Share % |
|---|---|
| Retail and Others | 100% |
| Total | 100.00% |
How to Buy BEL Shares?
Buying and selling of Earum Pharma can be done by a stock broker registered with SEBI. Here are the names of some popular brokers.
- groww
- Zerodha
- Angel One
- upstox
Earum Pharma Similar Stocks
| Company Name | Mkt Cap | Profit (1Year) | 52W L | 52W H |
|---|---|---|---|---|
| Kaynes Technology India | ₹39.80KCr. | 124.99% | ₹2424 | ₹7822 |
| Hindustan Aeronautics | ₹2.56LCr. | 22.77% | ₹2820 | ₹5674.75 |
| Boeing Co | ₹12.70 KCr. | 15.74% | ₹137.03 | ₹217.59 |
| Airbus SE | ₹12.38KCr | 6.05% | ₹124.72 | ₹172.78 |
| Bharat Dynamics | ₹42.29 KCr | 31% | ₹776.05 | ₹1794.70 |
| Apollo Micro Systems | ₹3.94 KCr. | 4.75% | ₹87.99 | ₹147.55 |
| Bharat Electronics | ₹1.97 KCr | 43.07% | ₹171.70 | ₹340.35 |
Earum Pharma Share Price Target: Export Opinion
Conclusion
Earum Pharma’s century-old legacy contrasts starkly with its current financial fragility. Despite hints of undervaluation, the company’s high debt, inconsistent margins, and lack of dividends make it a speculative choice. Prudent investors may opt to monitor its progress from the sidelines, prioritizing financially stable alternatives in the pharmaceutical sector until Earum demonstrates sustained operational recovery.
Disclaimer: The information provided here is for general informational purposes only and should not be considered as financial advice. Before making any investment, it is advisable to consult with a certified financial advisor. The author is not responsible for any investment decisions made based on this article.
FAQs
Q1. What is the Earum Pharma share price target for 2025?
Ans: The expected share price target for Earum Pharma in 2025 is between ₹1.30 to ₹2.98.
Q2. What is the Earum Pharma share price target for 2030?
Ans: Earum Pharma’s share price target for 2030 is projected to be between ₹3.86 to ₹6.79.
Q3. What is the Earum Pharma share price target for 2040?
Ans: The share price target for Earum Pharma in 2040 is expected to be between ₹10.6 to ₹17.80.
Q4. What is the Earum Pharma share price target for 2050?
Ans: Earum Pharma’s share price target for 2050 is likely to range between ₹15.4 to ₹30.7.